奥扎格雷联合低分子肝素钙治疗脑血栓的临床研究

Clinical Research of Ozagrel Combined with Low Molecular Weight Heparin Calcium for Cerebral Thrombosis

目的对应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果进行研究。方法整群选择在该院2012年12月—2014年12月就诊的患有脑血栓疾病的患者86例,随机分为对照组和治疗组,每组43例。采用奥扎格雷对对照组患者实施治疗;采用低分子肝素钙与奥扎格雷联合对治疗组患者实施治疗。对比神经功能缺损评分在药物治疗前后的变化幅度、脑神经功能恢复正常时间和脑血栓药物治疗计划实施总时间、脑血栓疾病药物治疗效果、用药期间的不良反应人数。结果治疗组患者神经功能缺损评分在药物治疗前后的变化幅度明显大于对照组;脑神经功能恢复正常时间(9.66±2.41)d和脑血栓药物治疗计划实施总时间(13.28±2.14)d明显短于对照组(13.62±3.47)、(17.39±3.20)d;脑血栓疾病药物治疗效果(总有效率90.6%)明显优于对照组(总有效率69.8%);用药期间的不良反应人数(1例)明显少于对照组(8例)。结论应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果非常明显。

Objective To study the clinical effect of ozagrel combined with Low molecular weight heparin calcium in the treatment of patients with cerebral thrombosis. Methods 86 patients admitted in our hospital suffering from cerebral disease, were randomly divided into control group and treatment group, with 43 cases in each group. Ozagrel was used for the treatment of patients in the control group, while ozagrel combined with Low molecular weight heparin calcium for those in the treatment group. The change range of neurological deficit scores before and after medication, recovery time of cerebral nerve function, expected general time of the treatment, medication effect, incidence of adverse reaction during medication of the two groups were compared. Results The change range of neurological deficit scores before and after medication of the treatment group was larger than that of the control group;recovery time of cerebral nerve function and expected general time of the treatment of the treatment group, （9.66±2.41）d and （13.28±2.14）d, were significantly shorter than those of the control group, （13.62±3.47 ）d, （17.39±3.20） d;the total medication effect of the treatment group, 90.6%, was higher than that of the control group 69.8%. There was one case of adverse reaction in the treatment group, which was obviously less than 8 cases in the control group. Conclusion The clinical effect of ozagrel.